You are here: Industry Insights > NIAID

News List

Trial to assess AstraZeneca’s long-acting COVID-19 antibody therapy europeanpharmaceuticalreview
February 10, 2021
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.
Bamlanivimab Reduced Risk of COVID-19 at Nursing Homes in Phase 3 Trial americanpharmaceuticalreview
January 22, 2021
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company announced.
Gritstone Advances Second Generation COVID-19 Vaccine americanpharmaceuticalreview
January 20, 2021
Gritstone Oncology is advancing development of a second-generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency against Spike mutants.
CohBar, NIAID to assess CB5064 Analogs for Covid-19 treatment pharmaceutical-technology
January 13, 2021
CohBar and the US National Institute of Allergy and Infectious Diseases (NIAID) have signed a non-clinical evaluation agreement (NCEA) to analyse CB5064 Analogs for treating Covid-19 related Acute Respiratory Distress Syndrome (ARDS).
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development prnewswire
December 29, 2020
Soligenix, Inc., a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced that the National Institute of Allergy and Infectious Diseases (NIAID) ...
NIAID Selects Metabolon for COVID-19 Study americanpharmaceuticalreview
December 09, 2020
Metabolon will participate in the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, Immunophenotyping Assessment in a COVID-19 Cohort, or IMPACC, study (grant no: 5U19AI118602-04).
NIAID study shows Moderna’s Covid-19 vaccine provides three-month immunity pharmaceutical-technology
December 07, 2020
Researchers at the National Institute for Allergies and Infectious Diseases (NIAID) have reported that Moderna’s Covid-19 vaccine, mRNA-1273, caused the human immune system to produce potent antibodies that endure for at least three months.
NIAID trial to identify potential COVID-19 treatments for further development europeanpharmaceuticalreview
October 21, 2020
The adaptive ACTIV-5/BET study will test two monoclonal antibody therapies in hospitalised COVID-19 patients to establish if they warrant larger clinical trials.
BenevolentAI's Platform-Derived Hypothesis for COVID-19 Treatment Validated in NIAID Trial americanpharmaceuticalreview
September 22, 2020
BenevolentAI has confirmed data released from a large scale randomized clinical trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), further validating its AI-derived hypothesis for baricitinib as a treatment for COVID-19
Baricitinib, Remdesivir Trial Reduces Recovery Time in Hospitalized COVID-19 Patients americanpharmaceuticalreview
September 21, 2020
Eli Lilly and Company and Incyte announced initial data emerging from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Previous page 1 2 3 4 5 Next page